Lunch & Dinner Presentation
noon – 1:30PM and 2/13/2018 5:30 PM – 7:30 PM
Company presentation by Pnina Fishman, Ph.D., CEO and Motti Farbstein, CFO
Can-Fite BioPharma, Ltd (NYSE: CANF) is an advanced clinical stage drug development company with a platform that addresses the treatment of cancer, liver disease, inflammatory diseases. CANF's lead drug candidate, Piclidenoson (CF101) is expected to enter Phase III trials in two indications, rheumatoid arthritis and psoriasis, while Namodenoson (CF102) completed patient enrollment in a Phase II trial for patients with advanced liver cancer, and is slated to enter Phase II for the treatment of NAFLD/NASH.